Amgen Inc. vs Huawei Technologies Co., Ltd.: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Huawei Technologies Co., Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Huawei Technologies Co., Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Huawei Technologies Co., Ltd. is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $118.3B for Huawei Technologies Co., Ltd., while their respective market capitalizations stand at $153.0B and $120.0B. Amgen Inc. is headquartered in United States and Huawei Technologies Co., Ltd. operates from China, and those different home markets shape how each company competes.

Amgen Inc.: A Japanese brewery kept Amgen alive. The upfront payment kept Amgen's laboratory lights on. Five years later, EPO became the first blockbuster drug in biotechnology history. The Kirin deal was not charity; it was a calculated exchange of geographic rights for survival capital. Without it, there might be no Amgen. The FTC sued to block the deal, arguing that Amgen could use its portfolio rebate structures to foreclose competing drugs from formularies. The companies won in court and closed the transaction. The companies won. The acquisition closed. It was the most expensive biotech deal of the year and among the largest in a decade, financed primarily with debt that raised Amgen's leverage ratio significantly. Thousand Oaks, California, 1980. In 1983, scientist Fu-Kuen Lin cloned the gene for erythropoietin, the hormone that signals bone marrow to produce red blood cells. Chemotherapy destroys bone marrow's ability to produce those cells, leaving cancer patients severely anemic and requiring frequent blood transfusions. A synthetic EPO could eliminate the need for transfusions. The FDA approved Epogen in 1989.

Huawei Technologies Co., Ltd.: Ren Zhengfei retains a nominal 0.7% equity stake in Huawei. The remaining 99.3% is owned by employees through a trade union committee representing over 140,000 participants. That ownership structure - unusual among companies of this scale anywhere in the world - explains some of the decision-making speed and long-term capital allocation tolerance that characterizes Huawei's response to the U.S. Technology embargo. No public shareholders demanding quarterly results. No private equity timeline. The founder holds effective control through veto rights, not equity concentration. The 2019 U.S. Entity List placement was the defining external event of the modern Huawei story. It severed the company from Google's Android services, from TSMC's advanced chip fabrication, from U.S.-origin equipment across its supply chain. The conventional analysis at the time was that Huawei's consumer electronics business would collapse within years. Instead, the company mass-produced 7-nanometer processors using deprecated DUV lithography equipment in the Kirin 9000s and Kirin 9010 chipsets, restoring its premium smartphone competitiveness domestically. The $118.3 billion in FY2025 revenue - up from $94.2 billion in 2022 - was generated while operating under comprehensive U.S. Sanctions. The growth came from sectors where Western alternatives are either unavailable or prohibited: 5G network infrastructure for markets outside the Five Eyes alliance, Digital Power solutions (smart photovoltaic inverters and data center liquid cooling), and domestic Chinese smartphone sales where Huawei commands significant loyalty. 23.4% of revenue - $27.7 billion - went to research and development in FY2024. The R&D workforce of over 114,000 engineers represents 55% of the total about 212,000 employees. Those numbers don't describe a company managing decline. They describe a company restructuring its technological supply chain from first principles.

Amgen Inc. and Huawei Technologies Co., Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Huawei Technologies Co., Ltd..

Amgen Inc. business model: This segment has lower margins than branded biologics but provides volume growth and demonstrates Amgen's commitment to lower-cost medicine access — a narrative that carries important political value during a period of intense congressional scrutiny of drug pricing. The problem is, Amgen's operating margins have typically run between 30% and 35% on a GAAP basis and higher on an adjusted basis, reflecting both the pricing power of its branded biologics and decades of operational refinement. Amgen's financial profile in fiscal year 2024 reflected both the far-reaching impact of the Horizon Therapeutics acquisition and the ongoing pressure from patent expirations and pricing pattern. Ten drugs were subject to the first round of negotiations for 2026 pricing, and Enbrel was among the drugs selected for the second cycle of negotiations targeting 2027. It added Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout — rare disease assets with high per-patient pricing and limited competition.

Huawei Technologies Co., Ltd. business model: This segment operates on a B2C model, relying on high-volume hardware sales combined with high-margin internet services and app store commissions. The launch of the Mate 60 series and the Pura 70 series, powered by the domestically manufactured Kirin 9000s and Kirin 9010 chipsets, restored Huawei's pricing power in the premium smartphone segment, allowing it to capture significant market share from Apple in the $800+ price tier in China. The financial mechanics of Huawei's model are exceptionally efficient in its core markets, where its brand equity and technological superiority allow it to command premium pricing, but the model faces severe margin compression in international markets where geopolitical restrictions limit its addressable market and force it to offer aggressive discounts to maintain carrier relationships. Huawei differentiates itself by integrating AI and cloud management into its digital power products, offering highly efficient, smart inverters that improved energy yield and liquid-cooling solutions that reduce data center power consumption, allowing it to command premium pricing and capture significant market share in the rapidly growing renewable energy and AI infrastructure sectors. the financial mechanics of Huawei's business model are exceptionally efficient in its core markets, where its brand equity and technological superiority allow it to command premium pricing, but the model faces severe margin compression in international markets where geopolitical restrictions limit its addressable market and force it to offer aggressive discounts to maintain carrier relationships. This geographic restriction not only limits Huawei's total addressable market for carrier equipment but also reduces the economies of scale that historically allowed it to undercut Ericsson and Nokia on pricing, forcing the company to compete on software features and network improvement rather than sheer volume. The third major challenge is the intense domestic competition in the cloud computing and enterprise segments, where Alibaba Cloud, Tencent Cloud, and state-backed entities like China Telecom's eCloud possess massive existing market share, deep integration with local government procurement systems, and aggressive pricing strategies that compress margins and require Huawei to continuously innovate its Pangu AI models and Ascend chip architecture to maintain its position as a top-tier provider. The second component of Huawei's moat is its unparalleled portfolio of standard-essential patents; the company holds over 14% of all 5G essential patents, meaning that any manufacturer building a 5G device, whether it is Apple, Samsung, or Ericsson, must license Huawei's intellectual property, generating hundreds of millions of dollars in annual licensing fees and giving Huawei significant use in cross-licensing negotiations.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Huawei Technologies Co., Ltd..

Amgen Inc. competitive advantage: Before the first human clinical trial ever tested a biotech-derived protein drug, a small group of venture-backed scientists in a repurposed building in Newbury Park, California, were betting that living cells could be engineered to manufacture medicines at industrial scale — a concept so novel in 1980 that most of Wall Street barely had a vocabulary for it. What makes Amgen genuinely unusual among its peers is the combination of scientific credibility, manufacturing scale, and financial discipline it has maintained over four decades. That singular achievement — turning living cells into life-saving medicines at global scale — is the defining fact of Amgen's half-century existence. Amgen's business model is built on one of the most capital-intensive and intellectually demanding processes in American enterprise: translating fundamental biological discoveries into regulated, manufactured medicines that can be sold at scale. Amgen's manufacturing organization is among the most sophisticated in the biopharma industry, running validated large-scale biologic production at facilities in Thousand Oaks, California; West Greenwich, Rhode Island; Juncos, Puerto Rico; Breda, Netherlands; and Singapore. While Amgen's MariTide program represents a genuine opportunity, it enters a market where Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) have already established billion-dollar revenue bases and massive manufacturing advantages. Amgen's most durable competitive advantage is its manufacturing expertise in large-molecule biologics. Financially, Amgen's scale generates operating use that smaller biotech firms cannot match. EPO had been identified and partially characterized in previous research, but no one had successfully cloned the human EPO gene and produced recombinant EPO protein at meaningful scale. The recombinant DNA tools available in 1980 were primitive by modern standards, but they were sufficient to do something that had never been done: clone human genes, insert them into bacterial or mammalian cell cultures, and produce therapeutic proteins at commercial scale.

Huawei Technologies Co., Ltd. competitive advantage: The strategic focus for the next three to five years is to increase the revenue contribution of the Cloud and Digital Power segments, scale the HarmonyOS ecosystem to achieve a critical mass of third-party developers, and continue the arduous process of domesticating the semiconductor supply chain to achieve true self-sufficiency in advanced logic and memory production. The business model of Huawei is a masterclass in vertical integration, massive capital allocation, and strategic patience, creating a sustainable, technologically sovereign ecosystem that generates significant revenue without relying on Western intellectual property or manufacturing capabilities. While Huawei successfully engineered the 7-nanometer Kirin 9000s using SMIC's deprecated DUV multi-patterning techniques, this process is inherently less efficient, more expensive, and yields significantly fewer chips per wafer than TSMC's EUV-based 5nm and 3nm nodes, creating a structural cost disadvantage and a persistent yield challenge that limits the volume of premium smartphones Huawei can produce and compresses the gross margins of its consumer electronics division. The vertical integration operates on multiple levels: Huawei designs its own processors through HiSilicon, develops its own operating systems through HarmonyOS and openEuler, manufactures its own production equipment through Nova, builds its own enterprise resource planning systems, and deploys its own network infrastructure, creating a closed-loop ecosystem where every component is optimized for the others, resulting in performance and efficiency gains that are impossible for companies relying on third-party silicon and software to achieve. The technical foundation of this moat is built on a highly optimized, massive R&D engine that employs over 114,000 engineers, representing 55% of the company's total workforce, who are tasked with solving the physics and materials science limitations imposed by the lack of access to leading-edge Western semiconductor manufacturing equipment. This technical superiority, combined with the patent portfolio and the vertical integration, creates a cohesive ecosystem that is exceptionally difficult for competitors to disrupt, as any attempt to replicate the platform must not only match its technical performance but also overcome the massive capital barriers and the decade-long head start in fundamental research. The ongoing evolution of Huawei's competitive advantage will be driven by its ability to scale its domestic semiconductor manufacturing capabilities, expand the HarmonyOS ecosystem to achieve a critical mass of third-party developers, and maintain its leadership in 5G-Advanced and 6G research, all while navigating the complex geopolitical environment surrounding international trade. The second initiative is to scale the Digital Power segment, with a target to capture 30% of the global smart photovoltaic inverter market and 25% of the data center liquid-cooling market by 2027. The third initiative is to achieve critical mass for the HarmonyOS NEXT ecosystem outside of China, with a target to onboard 500,000 native applications and reach 200 million active devices in international markets by 2026. Huawei Technologies Co. Ltd.'s strategic bet for the next three to five years is centered on three primary pillars: achieving total semiconductor supply chain self-reliance, scaling the HarmonyOS ecosystem to become the third major global mobile operating system, and establishing dominance in the intersection of artificial intelligence, automotive intelligence, and digital power infrastructure.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Huawei Technologies Co., Ltd. each plan to expand from here.

Amgen Inc. growth strategy: But those same drugs carry price tags that have triggered congressional hearings, federal investigations, and public outrage. Amgen generates revenue through four primary mechanisms: branded biologic product sales in the United States, international product sales in Europe and other markets, licensing and royalty income from partnerships, and a rapidly expanding biosimilars portfolio. Key pipeline assets include MariTide (maridebart cafraglutide), an investigational obesity and diabetes drug that targets both GLP-1 receptor agonism and GIP receptor antagonism — a mechanism that could position Amgen to compete directly with Eli Lilly's tirzepatide and Novo Nordisk's semaglutide in the exploding weight loss drug market. The company has also advanced AMG 133 through Phase 2 trials with weight loss data that attracted significant investor attention in 2024 and 2025. The capital investment required to build and validate these facilities — routinely running into hundreds of millions or billions of dollars per site — creates a structural barrier that reinforces Amgen's competitive position. The company has invested in next-generation multiproduct manufacturing facilities that can be adapted to different biologic drug types with shorter reconfiguration times, improving capital efficiency. Capital allocation historically favored a combination of R&D reinvestment, dividend payments (the quarterly dividend reached $2.25 per share in 2024, yielding approximately 3%), and share repurchases. While the United States accounted for approximately 75% of product revenues in 2024, the company has been growing its ex-U.S. Presence, particularly in Europe where biosimilars face more receptive regulatory and market environments than in the U.S. Amgen's European commercial infrastructure, bolstered by its 2013 acquisition of deCODE Genetics in Iceland and longstanding partnerships across major EU markets, provides both revenue diversification and access to genomic research populations that inform drug discovery. Amgen Inc. was established at the dawn of the biotechnology era and has grown to become the archetype of what a successful independent biotech company can achieve. The company is organized into research and development divisions focused on oncology, cardiovascular and metabolic diseases, inflammation, bone health, rare diseases, and neuroscience. Amgen's competitive posture has evolved from a largely defensive stance in the early 2010s — when it was focused primarily on defending Enbrel and Neulasta from biosimilar competition — toward a more aggressive offensive strategy combining pipeline development, strategic acquisitions, and biosimilar market entry. The question of how much revenue Amgen can sustain through the mid-2020s patent cliff cycle while simultaneously growing new franchises defines the company's near-term financial trajectory. Amgen's growth strategy rests on four interdependent pillars that CEO Robert Bradway has consistently articulated to investors since 2020. Tepezza has significant underpenetrated market opportunity — the vast majority of thyroid eye disease patients remain undertreated despite Tepezza's strong clinical evidence — and Amgen has invested heavily in patient identification programs, specialist education, and payer coverage expansion since the acquisition closed. The third pillar is building the biosimilars business into a durable revenue contributor. Amgen has committed to launching biosimilar versions of multiple high-revenue biologics as they lose exclusivity through 2030, using its manufacturing capabilities to achieve cost structures that enable profitable competition at biosimilar price points. The fourth pillar is disciplined financial management — specifically debt reduction from the Horizon acquisition while preserving R&D investment and the dividend. Management has targeted returning to investment-grade credit metrics by 2027, which would restore full capital allocation flexibility including potential smaller bolt-on acquisitions in therapeutic categories where Amgen wants to build pipeline depth. The geographic growth opportunity in emerging markets, particularly China and Japan, where Amgen is building direct commercial presence, represents a longer-term revenue diversification vector. Amgen is attempting to offset this through volume growth in Repatha, Otezla, Tepezza, and biosimilars, while simultaneously advancing pipeline assets in oncology including tarlatamab (AMG 757), a bispecific T-cell engager targeting DLL3 for small cell lung cancer that received FDA accelerated approval in May 2024. Tarlatamab's launch performance will be an important indicator of Amgen's ability to build new oncology franchises beyond its historical reliance on supportive care drugs. Bowes, a partner at the venture firm U.S. Venture Partners, conceived the idea of building a biotech company from the ground up with experienced professional management at its helm rather than waiting for academics to evolve into businesspeople. Rathmann was not a molecular biologist, but he was a scientist with deep industry experience and an intuitive understanding of how to build research organizations. The company's initial scientific strategy was deliberately broad: it would pursue multiple research directions in protein biology simultaneously, betting that some would eventually yield commercial products without pre-committing to any single therapeutic hypothesis. Amgen moved its operations to a leased building in Newbury Park, California (later incorporated into Thousand Oaks), hiring scientists from Caltech, UCLA, and major pharmaceutical companies. This partnership, unconventional in the extreme — a biotechnology company licensing its core technology to a brewery — demonstrated the creative financial pragmatism that would characterize Amgen's management style for decades. The dual-product base gave the company the financial stability to invest in a research pipeline that would take two more decades to produce its next generation of commercially significant medicines.

Huawei Technologies Co., Ltd. growth strategy: The financial data, the technical specifications, and the strategic decisions that define Huawei's operations provide a comprehensive blueprint for understanding the intersection of corporate strategy, national security, and technological sovereignty in the twenty-first century. The journey from the distribution of analog switches to the mass production of 7-nanometer AI processors is a demonstration of the power of strategic patience, massive capital allocation, and the immense value of building complete technological stacks in an era of geopolitical fragmentation. The platform's current trajectory points toward continued growth and innovation, driven by a deep understanding of its core markets and a commitment to providing the most advanced communication and computing infrastructure in the world. The technical specifications, the financial metrics, and the strategic decisions that have shaped Huawei's evolution provide a comprehensive blueprint for how to build a dominant, vertically integrated technology conglomerate in the twenty-first century, a blueprint that will be studied, emulated, and contested by governments and corporations across the globe. The company's success is a direct result of its consistent focus on core technology research, its refusal to compromise on long-term strategic goals for short-term financial gain, and its relentless drive to enable its engineers to solve the most complex problems in physics and materials science. The company's current position as the dominant force in global telecommunications infrastructure is a direct result of the strategic decisions made over the past three decades, when Ren Zhengfei prioritized massive R&D investment and rural market penetration over short-term profitability, a strategy that is now being realized by the about 212,000 employees who rely on Huawei's technological leadership every single day to build the infrastructure of the future. Despite being placed on the U.S. Entity List in May 2019, Huawei successfully engineered a complete domestic supply chain substitution, launching the HarmonyOS operating system to over 900 million active devices. Huawei's ability to compete against these giants is predicated on its superior product execution, its massive R&D investment, its vertical integration, and its unique employee-ownership structure, which creates a level of operational efficiency and long-term strategic focus that is exceptionally difficult for larger, more bureaucratic organizations or public companies focused on quarterly earnings to replicate. Huawei's current position as the dominant force in global telecommunications infrastructure and a resurgent force in consumer electronics is a direct result of its consistent focus on core technology research, its refusal to compromise on long-term strategic goals for short-term financial gain, and its relentless drive to enable its engineers to solve the most complex problems in physics and materials science. However, the FY2024 results demonstrate that the company has successfully stabilized its revenue base and returned to high-single-digit growth, driven by the massive expansion of its Digital Power segment, which grew by over 40% year-over-year, and the recovery of its Consumer Business, which grew by over 30% following the launch of the Kirin-powered Mate 60 series. This massive R&D expenditure, while compressing short-term operating margins, is the fundamental engine of Huawei's long-term financial survival and growth, ensuring that its proprietary technology stack remains competitive despite the lack of access to leading-edge Western semiconductor manufacturing equipment. The company's balance sheet remains exceptionally strong, with over $40 billion in cash and cash equivalents, providing it with significant financial flexibility to continue investing in growth initiatives, manage the complex regulatory environment, and weather any macroeconomic headwinds without the need for external capital. The ongoing evolution of Huawei's financial strategy will be driven by a deep understanding of its core markets and a commitment to providing the most advanced communication and computing infrastructure in the world. The ongoing challenge for Huawei is to navigate these complex technical, geopolitical, and competitive headwinds while maintaining the strict R&D investment levels required to stay among the leaders of 5G-Advanced, 6G, and AI research, a balancing act that requires flawless execution and an consistent commitment to long-term strategic goals over short-term financial improvement. The company's strategic focus on the creator economy and the App Directory represents its primary mechanism for increasing revenue per user without compromising its privacy commitments, a strategy that aligns the company's financial incentives with the success of its community leaders and developers. The irony is, the ongoing evolution of Huawei's product roadmap, its financial strategy, and its regulatory compliance efforts will be closely monitored by investors, technologists, and policymakers alike, as the company's decisions will have a profound impact on the future of digital communication and the broader technology sector. The journey from the failure of Fates Forever to the dominance of Discord is a demonstration of the power of strategic agility and the immense value of building infrastructure that enable human connection, a value that has proven to be far more enduring and lucrative than any single video game could ever achieve. The platform's current trajectory points toward continued growth and innovation, driven by a deep understanding of its user base and a commitment to providing the best possible communication experience in an increasingly fragmented digital world. The story of Huawei is still being written, but its foundational chapters have already secured its place as one of the most important and influential technology companies of the modern era, a platform that has fundamentally changed how we interact, collaborate, and build communities in the digital age. The technical specifications, the financial metrics, and the strategic decisions that have shaped Huawei's evolution provide a comprehensive blueprint for how to build a dominant, user-centric technology platform in the twenty-first century, a blueprint that will be studied and emulated by entrepreneurs and executives across the globe. The company's success is a direct result of its consistent focus on the core user experience, its refusal to compromise on privacy and performance, and its relentless drive to enable its community leaders to build and monetize their own digital spaces. The story of Huawei is a story of innovation, resilience, and the far-reaching power of digital communication, a story that continues to unfold as the platform expands its reach and deepens its impact on the way we connect with one another in the digital world. The company's current position as the dominant force in real-time communication is a direct result of the strategic decisions made in the spring of 2015, when Jason Citron looked at the analytics for a failing mobile game and saw the future of digital communication, a future that is now being realized by the 150 million monthly active users who rely on Huawei every single day to talk, hang out, and build communities. This patent dominance is the result of a relentless, twenty-year investment in fundamental research, a strategy that has positioned Huawei not just as a manufacturer, but as a foundational architect of the global telecommunications standards that underpin the modern digital economy. The strategic decision to remain private allows Huawei to maintain complete control over its product roadmap and R&D investments, insulating the company from the quarterly earnings pressures that force public technology companies to prioritize short-term financial metrics over long-term technological sovereignty. Huawei Technologies Co. Ltd.'s growth strategy is centered on three specific, named initiatives with clear targets: scaling the Harmony Intelligent Mobility Alliance, expanding the Digital Power segment's global market share, and achieving critical mass for the HarmonyOS NEXT network outside of China. The first initiative is to transform the automotive intelligence business into a major revenue driver by expanding the Harmony Intelligent Mobility Alliance to include at least five major automakers by 2026, with a target to integrate its smart cockpit and autonomous driving solutions into over one million vehicles annually. This requires continuous innovation in power electronics, integrating AI for maximum energy yield and cooling efficiency, and expanding its sales and service network in Europe, the Middle East, and Latin America to capitalize on the global energy transition and the massive build-out of AI data centers. To support these initiatives, Huawei is investing heavily in its technical infrastructure, expanding its global network of research centers, and developing new machine learning models to improve the efficiency of its AI and digital power products. The company is also expanding its engineering headcount, focusing on hiring top talent in artificial intelligence, semiconductor physics, and power electronics to drive the development of new features and improve the overall product performance. The ongoing evolution of Huawei's growth strategy will be driven by a deep understanding of its core markets and a commitment to providing the most advanced communication and computing infrastructure in the world. The first initiative is to completely domestic the semiconductor manufacturing process, moving beyond the current 7-nanometer DUV multi-patterning techniques to achieve viable 5-nanometer and eventually 3-nanometer production using domestic equipment and advanced packaging technologies like chiplets, a monumental engineering challenge that requires the coordination of hundreds of domestic suppliers and billions of dollars in continuous R&D investment. This strategy is not merely about catching up to TSMC; it is about creating a completely independent, sanctions-proof technology stack that ensures Huawei's access to advanced compute for its AI and 5G-Advanced products, regardless of the geopolitical environment. The second strategic focus is the global expansion of HarmonyOS; while the operating system has achieved massive adoption in China with over 900 million devices, the company is aggressively targeting emerging markets in Southeast Asia, the Middle East, and Latin America, where the geopolitical stigma associated with Huawei is less pronounced and where the demand for a non-Android, non-iOS alternative that offers superior privacy and integration is growing. The company's Harmony Intelligent Mobility Alliance is expanding rapidly, partnering with multiple domestic automakers to produce smart vehicles that are essentially data centers on wheels, generating high-margin software licensing revenue and creating a massive new data stream for its AI models. The lessons learned from these early struggles, including the importance of rural market penetration, the value of employee ownership, and the necessity of massive R&D investment, continue to guide the company's strategic direction and its investment priorities, ensuring that Huawei remains the definitive digital infrastructure provider for the developing world.

A closer look at the financial trajectory of Amgen Inc. and Huawei Technologies Co., Ltd. rounds out the comparison.

Amgen Inc.: Amgen reported FY2025 total revenues of $36.8 billion, up 10% year over year, and GAAP net income of $7.7 billion. Product sales grew on volume, with eighteen products reaching record annual sales and fourteen exceeding $1 billion. The Horizon acquisition continued to reshape the portfolio, while amortization, impairment charges, pricing pressure, and R&D investment kept GAAP margins below the cleaner non-GAAP picture.

Huawei Technologies Co., Ltd.: Huawei reported CNY 860.6 billion in FY2025 revenue, equivalent to about $118.3 billion, and CNY 68.0 billion in net profit. Revenue was broadly flat against 2024, but profitability improved as the company continued to fund a very large R&D program. The 2025 annual report disclosed CNY 192.3 billion in R&D spending, equal to 21.8% of revenue, and 114,000 R&D employees, about 53.7% of the workforce.